CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-06 | Tananbaum James B. Director | Purchase | +20,000 | $4.34 | $87K | 4,247,670 |
| 2025-05-06 | Foresite Labs, LLC 10% owner | Purchase | +20,000 | $4.34 | $87K | 4,247,670 |
| 2025-05-06 | Foresite Capital Management VI LLC 10% owner | Purchase | +20,000 | $4.34 | $87K | 4,247,670 |
| 2025-05-05 | AKKARAJU SRINIVAS Director | Purchase | +138,368 | $4.58 | $634K | 3,564,786 |
| 2025-05-05 | AKKARAJU SRINIVAS Director | Purchase | +22,002 | $5.27 | $116K | 3,586,788 |
| 2025-05-02 | AKKARAJU SRINIVAS Director | Purchase | +159,920 | $4.55 | $728K | 3,426,418 |
| 2025-05-02 | Tananbaum James B. Director | Purchase | +25,000 | $4.62 | $116K | 4,227,670 |
| 2025-05-02 | Foresite Labs, LLC 10% owner | Purchase | +25,000 | $4.62 | $116K | 4,227,670 |
| 2025-05-02 | Foresite Capital Management VI LLC 10% owner | Purchase | +25,000 | $4.62 | $116K | 4,227,670 |
| 2025-04-02 | Colowick Alan Director | Purchase | +2,300 | $7.49 | $17K | 18,404 |
| 2025-04-01 | Colowick Alan Director | Purchase | +16,104 | $6.97 | $112K | 16,104 |
| 2025-04-01 | Babler Martin President, CEO and Chairman | Purchase | +15,650 | $6.44 | $101K | 106,454 |
| 2025-02-18 | Hardiman Roy C. Chief Business & Strategy Ofcr | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-02-18 | Richardson Derrick SVP, People and Culture | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-02-18 | Schroer John R. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-02-18 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2025-02-18 | Klein Sara Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2025-02-18 | Drappa Jorn Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2025-02-18 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2025-02-18 | Babler Martin President, CEO and Chairman | Grant or award · Stock Option (Right to Buy) | +523,000 | 523,000 |
Page 7 of 21 · 405 trades